The results of the clinical trial POETIC aiming to assess the benefit of pre- and perioperative aromatase inhibitor (AI) treatment on the clinical outcome in operable breast cancer are strongly indicative of a prognostic value of the relative Ki67 reduction [53]. This evidence concerns the gene CYP19A1 and breast carcinoma.